Managing Postoperative Shivering and Comfort

Abstract

Postoperative shivering is a common and distressing complication following anesthesia, adversely affecting patient comfort, metabolic demands, and recovery. This review explores the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, and comprehensive management strategies for postoperative shivering, integrating recent evidence, guideline-based recommendations, and emerging therapies. Emphasis is placed on the clinical implications of shivering, the underlying mechanisms, and practical, evidence-informed interventions to enhance patient outcomes and perioperative comfort.

Introduction

Postoperative shivering (POS) is an involuntary muscular activity that frequently occurs after both general and regional anesthesia. It not only causes significant patient discomfort but also increases oxygen consumption, carbon dioxide production, and cardiac workload, potentially leading to adverse outcomes in vulnerable populations. Understanding the multifactorial etiology and optimal management strategies is essential for improving perioperative care and reducing morbidity associated with POS.

Epidemiology / Disease Burden

POS has been reported in 5% to 65% of patients post-anesthesia, with the incidence varying based on anesthetic technique, ambient temperature, and patient-specific factors. The highest rates are observed in the immediate postoperative period and following neuraxial anesthesia. The burden is clinically significant, as shivering not only impairs patient satisfaction but can exacerbate myocardial ischemia, interfere with monitoring, and delay recovery room discharge. Epidemiological data underscore the need for proactive surveillance and intervention, especially in high-risk populations such as the elderly and those with cardiovascular disease.

Pathophysiology

The pathophysiology of POS is multifactorial. Hypothermia, defined as a core temperature below 36°C, is a primary trigger, resulting from intraoperative heat loss due to redistribution, evaporation, convection, and impaired thermoregulation under anesthesia. Non-hypothermic shivering may result from anesthetic-induced disruption of hypothalamic thermoregulatory set points, systemic inflammatory responses, or pain. Neurotransmitters including serotonin, norepinephrine, and opioids modulate thermoregulation, implicating their pathways in the genesis of POS. Metabolic consequences include a two- to three-fold increase in oxygen consumption and marked elevation in metabolic rate, which can be deleterious in compromised patients.

Risk Factors

Key risk factors for POS include intraoperative hypothermia, use of volatile anesthetics, longer surgery duration, lower ambient operating room temperatures, female gender, younger age, and inadequate preoperative warming. Regional anesthesia, particularly spinal and epidural, is associated with higher rates due to sympathetic blockade and impaired vasoconstriction. Patient comorbidities such as hypothyroidism, anemia, and cardiovascular disease may further predispose to or exacerbate the effects of shivering.

Clinical Features

Clinically, POS is characterized by visible or palpable muscular tremors, predominantly involving the trunk, jaw, and extremities. Patients commonly report cold sensations, discomfort, and anxiety. Severe shivering can cause increased heart rate, hypertension, and in rare cases, myocardial ischemia or arrhythmias. In non-verbal or sedated patients, shivering may present as unexplained tachycardia, hypertension, or increased oxygen demand detected via monitoring equipment.

Diagnosis

Diagnosis is primarily clinical, based on observation of rhythmic muscular contractions and patient-reported symptoms. Bedside assessment should include measurement of core temperature using reliable modalities such as esophageal, bladder, or tympanic thermometry. Differential diagnoses include rigors from sepsis, pain, anxiety, and medication-induced tremors. Severity grading systems, such as the Bedside Shivering Assessment Scale (BSAS), can aid in standardized documentation and monitoring of shivering intensity.

Treatment & Management

Management of POS is multifaceted, focusing on prevention, prompt recognition, and targeted intervention. Non-pharmacological strategies include maintaining normothermia via forced-air warming blankets, preoperative warming, and warmed intravenous fluids. Pharmacological options are considered when shivering is severe or refractory. First-line agents include meperidine, which acts via kappa opioid and alpha-2 adrenergic receptor agonism, and clonidine or dexmedetomidine, which modulate central thermoregulation. Tramadol and magnesium sulfate have also demonstrated efficacy. The choice of agent should be individualized, considering patient comorbidities, contraindications, and potential side effects. In practice, a combination of active warming and appropriately selected medication yields optimal outcomes.

Recent Advances / Emerging Therapies

Recent years have witnessed the emergence of novel agents and techniques for POS management. Dexmedetomidine, an alpha-2 agonist, has gained prominence due to its efficacy in reducing shivering with minimal respiratory depression. Multimodal warming protocols, integrating preoperative and intraoperative active warming, have shown promise in reducing incidence. Non-invasive temperature monitoring and real-time analytics now enable earlier identification and intervention. Ongoing research investigates the role of serotonergic and dopaminergic agents, as well as the potential of personalized warming protocols tailored to individual risk profiles.

Guideline Recommendations

Current guidelines from societies such as the American Society of Anesthesiologists (ASA) and the National Institute for Health and Care Excellence (NICE) emphasize rigorous perioperative temperature management, use of forced-air warming devices, and early pharmacologic intervention when shivering occurs. Protocolized approaches, including routine monitoring of core temperature and standardized warming interventions, are recommended for all patients undergoing anesthesia. Pharmacologic treatment should align with evidence-based first-line agents and consider patient-specific factors for optimal safety and efficacy.

Conclusion

Postoperative shivering remains a significant clinical challenge with implications for patient comfort, safety, and recovery. Effective management requires a thorough understanding of its multifactorial pathophysiology, risk stratification, and integration of both non-pharmacological and pharmacological strategies. Advances in monitoring and emerging therapies continue to refine the approach to POS, while adherence to clinical guidelines ensures evidence-based, patient-centered care. Ongoing research and education are vital to further improve outcomes and postoperative experiences for surgical patients.